Polarityte, Inc. (PTE)

Trade PTE now with
5/16/2022 7:35:07 AM PolarityTE Q1 Adj Loss/shr $0.10 Vs Loss/shr $0.11 Prior Year
5/13/2022 8:02:59 AM PolarityTE Says FDA Granted Regenerative Medicine Advanced Therapy Designation To SkinTE
3/30/2022 7:36:40 AM PolarityTE FY Loss Per Share $0.38 Vs Loss $1.16 Last Year
1/18/2022 8:02:32 AM PolarityTE : FDA Approves IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication
12/20/2021 8:05:16 AM PolarityTE Submits Complete Response To FDA's Clinical Hold Correspondence For SkinTE IND
11/10/2021 7:02:31 AM PolarityTE Q3 Loss/shr Narrows To $0.01 From $0.18 Last Year
10/7/2021 8:05:44 AM PolarityTE Says Strongly Believe In Potential For SkinTE In Chronic Cutaneous Ulcers
9/2/2021 8:06:13 AM PolarityTE Names Richard Hague CEO; Elects David Seaburg To Board